The full potential of cadaveric islet transplantation will only be realized by avoiding both pretransplant insults programming islets for subsequent death and posttransplant triggers for apoptosis and necrosis. The immediate blood mediated inflammatory response causes significant islet loss in the immediate posttransplant period. However, if we focus on this alone we will miss many opportunities to improve transplanted islet survival. Even when single donor islet transplants become the norm, there will still be more patients who might benefit from islet transplants than grafts available. Input from "transplanters" and diabetologists is essential in order to select appropriate patients for islet transplantation.
T he campaign to establish islet transplantation as an acceptable alternative to insulin treatment for type 1 diabetes mellitus has been waged to the point at which victory appears to be in sight. The fact that a forum such as this can consider the prospect of successful replacement therapy with islets from a single pancreas testifies to how much has been achieved. Islet transplantation has become a credible procedure. The success achieved with the Edmonton protocol (1, 2) reflects incremental improvements in many areas, including better identification of optimal donor characteristics, better organ retrieval techniques, minimization of cold ischemia times, better isolation technique and avoidance of immunosuppressive drugs which impair islet function and viability. Despite all this, islets from multiple pancreases are normally required for insulin independence. Korsgren and colleagues review the current status of clinical islet transplantation, and conclude that the major obstacle to routine insulin independence with a single pancreas is loss of islets immediately following transplantation. They argue that the immediate blood mediated inflammatory response (IBMIR) is a major contributor to this. We will compare this with the other insults that result in early islet loss and will go on to ask how islet transplantation will look as an alternative to insulin therapy when single pancreas transplants become the norm.
The immediate blood mediated inflammatory response may be said to have come of age in 2002 (3, 4) and a number of therapeutic strategies for its prevention have been proposed. Korsgren et al. present an informative and detailed theoretical analysis of the maximum potential islet yields, and conclude that experienced centres are obtaining something close to the maximum possible. It follows from this that prevention of posttransplant islet loss has become the most important goal of therapy. Whilst acknowledging the force of their argument, we believe that pancreas retrieval and islet isolation are arenas in which important victories still need to be won, and that an important element of the argument is missed by their focus on maximum yields. At present even experienced centres can obtain "clinical grade" preparations in no more than 50% of isolations, largely due to insufficient islets. The potential for improvements in this area are illustrated by the potential impact of use of the two-layer method for pancreas preservation. The two-layer method greatly improves islet yield (5, 6) . A study from Edmonton found that 62% of pancreases preserved using the two layer method yielded clinical grade preparations as against only 22% of pancreases preserved in University of Wisconsin solution, as described in the original Edmonton protocol (7). The twolayer method also improves islet quality from marginal donors (8) and makes pancreatic resuscitation possible after ischemic damage (9) . The two layer method is not as yet widely used, and-although unlikely to bring a major increase in the number of single pancreas transplants-its use will increase the number of patients transplanted: still a worthwhile goal.
The fate of islets in the immediate posttransplant period is not determined solely by events occurring posttransplantation. Changes in the energy status of islets and of the balance of pro-apoptotic and anti-apoptotic mediators occurring during retrieval, preservation and isolation will determine the ability of islets to resist subsequent pro-apoptotic insults: only the fittest will survive. Apoptosis may be triggered by multiple insults including inflammatory cytokines (predominantly IL-1beta, TNF-alpha, and IFN-gamma (10, 11) ), metabolic stress and hypoxia. The "cytokine storm" associated with brain stem death may thus be a significant early trigger to beta cell apoptosis. Islets then undergo an inevitable period of hypoxia during pancreas retrieval, storage and islet isolation. Activation of apoptotic pathways by these insults may not be evident prior to transplantation, but may "programme" islets for subsequent apoptosis to varying degrees, depending on the severity of the combined insults. In support of this argument, islet ATP content is a marker of "metabolic health" and reduction in the ATP:ADP ratio is one indicator of the impact of such insults. The ATP content of donated pancreata varies significantly, reflecting the variability in the quality of organ retrieval and preservation prior to islet isola-tion (12) . AMP kinase is a molecule expressed in beta cells that is of particular interest as it is activated by both hypoxia and "metabolic stress". Physiologically it plays an important role in glucose sensing. However, activation of AMP kinase will be deleterious to graft function through inhibition of beta cell insulin release (13, 14) and may also trigger beta cell apoptosis through a c-jun N-terminal kinase and caspase dependent pathway (15, 16) 9) , and reduces islet apoptosis (17) . Gene therapy, including over-expression of bcl-2, may also prevent early apoptotic islet loss (18) . Taken together, this work implies that the fate of transplanted islets is determined long before cell death becomes apparent. Further understanding of the pathways involved should lead to the emergence of therapeutic strategies which minimize islet loss.
This said, we do not dismiss the importance of the environmental insults that drive early islet loss in the immediate posttransplant period, or the importance of the immediate blood mediated inflammatory response. Reduction of islet loss from these early non-antigen specific insults will set the scene for further battles against the ongoing insults of rejection, recurrent autoimmune disease and senescence, which will also need to be won. The success of whole pancreas transplantation does however suggest that rejection and recurrent autoimmune disease can be prevented in most cases. Graft survival will be improved by new immunosuppressive strategies, but the main gain in this area will perhaps be by improved tolerance induction, freeing patients from the need for ongoing immunosuppression and the systemic toxicity this brings in its train.
Let us now assume that single pancreas transplants will become more widely used, and consider what changes this may bring. If we begin with the question of supply, data from the Swiss transplant registry suggest that 31% of multiorgan donors are suitable for islet transplantation (19) . This analysis took account of pancreata prioritized for whole pancreas transplantation and is consistent with estimates from other centres. Given that the UK had 772 solid organ donors in [2003] [2004] , no more than 250 pancreata would be available for islet transplantation per annum. By general agreement, severe recurrent hypoglycemia is the main indication for islet transplantation, but how common is this? Dispassionate debate is lacking in this area, partly because transplanters typically lack experience in diabetes management, while most diabetes specialists know little at first hand about the risks of intervention. Both sides therefore tend to play the numbers game to support their own side of the argument, either to emphasize the callousness of those who do nothing when an effective therapy is available to relieve the misery of their patients, or else to decry the recklessness of those prepared to undertake hazardous interventions for a potentially treatable condition. Nor, as we will see, is there a hard and fast definition of severe hypoglycemia. Add to this the passionate desire of many people with type 1 diabetes to obtain freedom from the tyranny of insulin dependence, and you are left with a highly volatile climate of opinion in which the loudest voice often tends to prevail.
The unique feature of insulin therapy for type 1 diabetes is that it sends a proportion of its users into coma every year, sometimes repeatedly. Over and above this it undermines the autonomy and self-confidence of those who know that it might, at any time and without warning, deprive them of their judgment or faculties. The impact of this should surely never be underestimated. On the other hand, human beings are remarkably adaptable and the great majority of people on insulin are able to get on with their lives in the hope that safer and more effective forms of therapy will eventually become available. The definition of what makes hypoglycemia intolerable, or in other words sufficiently disabling as to justify transplantation, is therefore inevitably somewhat fluid. Nor is the category homogeneous; some individuals experience hypoglycemia because of inadequate management, some because of a compulsive personality, some have psychosocial problems and others are feckless, while others again are disabled for reasons that are frankly unknown. On current estimates it may be reasonable to believe that of approximately 250,000 people with type 1 diabetes in the United Kingdom there may be as many as 7,500 patients with severe recurrent hypoglycemia; but only a small minority of these would currently justify transplantation. The best that we can say is that selection of appropriate patients for islet transplantation will not be a problem if the enthusiasm of the islet transplanter is tempered by the conservatism of the diabetologist.
Finally, regimens are being defined which allow combined islet and kidney transplantation (either simultaneous or islet after kidney (20, 21) ). In this group of patients the harmful effects of immunosuppression can be accepted because this is already necessitated by the kidney transplant. Approximately 1,300 patients receive renal transplants each year in the United Kingdom. Since 19.8% of new patients with end stage renal failure in the United Kingdom present with diabetic nephropathy, this suggests that approximately 250 patients are potentially suitable for islet transplants. Thus, even if patients are excluded because of the cardiovascular complications common in this group, the demand from even this category of patients would require optimal use of every pancreas retrieved. Overall, when established programs are up and running, demand will clearly outstrip supply and careful screening will be needed to ensure that only patients with a realistic possibility of benefit go forward to islet transplantation. In the meanwhile, it seems clear that even single pancreas islet transplants will only be available for a minority of those who might potentially benefit. Real though these benefits may be, the true impact of islet transplantation awaits the development of replenishable sources of islets. Whatever their source, these cells will remain vulnerable to the insults responsible for early cadaveric islet loss, including the immediate blood mediated inflammatory response, and we need to learn the lessons now that will ensure that the full potential of these cells is realized.
